Waters Corporation announced the acquisition of Halo Labs™, a cutting-edge innovator in specialized imaging technologies. Halo Labs develops unique solutions that detect, identify, and count interfering materials—such as subvisible particles—in complex therapeutic products like cell, protein, and gene therapies.
Enhancing Waters’ Analytical Capabilities
At the heart of Halo Labs’ offering is the Aura™ platform, which performs full-spectrum particle analysis. This capability directly complements the light scattering detection technologies within Waters’ Wyatt Technology™ Portfolio. The synergy between these platforms will unlock deeper insights in large molecule characterization. For instance, Aura’s technology can detect translucent impurities that amplify CAR T-cell therapies—impurities typically missed by conventional methods.
Strategic Fit for Bioprocessing and Quality Control
As per the press release, with this acquisition, Waters gains a powerful tool for large molecule development and QA/QC. Integrating Halo Labs’ advanced particle imaging into Waters’ portfolio allows for more comprehensive analytical and bioprocess testing. This move adds value for Waters’ customers. It also drives the company’s continued expansion into high-demand therapies like cell and gene therapies.
Leadership Endorsement
“Adding Halo Labs’ low-sample-volume, high-throughput particle analysis enhances our ability to support a wide range of biopharma needs,” said Dr. Udit Batra, President and CEO of Waters Corporation. “This acquisition reinforces our commitment to providing the analytical innovation our customers need, especially as CAR T-cell therapies and other advanced treatments accelerate. Together with our Wyatt Technology product line, we’re extending our leadership in specialized analytical tools for emerging biologics,” Dr. Batra added.
Shared Vision for Innovation and Safety
Rick Gordon, CEO of Halo Labs, added, “We’re excited to join Waters, a company equally driven by innovation and customer success. This partnership allows us to scale our technology’s impact, supporting safer and more effective drug development globally. Together, we’re poised to drive new breakthroughs that benefit patients around the world.”
